Influence of Metabolic Factor Control on Psoriatic Arthritis Risk in Psoriasis Patients: A Retrospective Cohort Study...

Area of Science:

• Rheumatology
• Metabolic Health
• Dermatology

Background:

• Psoriasis (PsO) is a chronic inflammatory disease with a higher risk of developing psoriatic arthritis (PsA).
• Metabolic factors are increasingly recognized as potential contributors to inflammatory conditions.
• Understanding the link between metabolic control and PsA development is crucial for patient management.

Purpose of the Study:

• To investigate the association between the control of key metabolic factors and the risk of developing psoriatic arthritis (PsA) in patients with psoriasis (PsO).
• To identify specific metabolic parameters that significantly influence PsA risk.

Main Methods:

• Retrospective cohort study utilizing data from the TriNetX US Collaborative Network up to December 31, 2022.
• Patients diagnosed with psoriasis (PsO) were categorized based on the control of metabolic factors: low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TGs), hemoglobin A1c (HbA1c), and uric acid (UA).
• Poor metabolic control was defined by specific thresholds for each factor (e.g., HDL ≤40 mg/dL, TG ≥150 mg/dL, HbA1c >7%). Hazard ratios (HR) were calculated to compare PsA incidence between poorly controlled and adequately controlled groups.

Main Results:

• Elevated triglycerides (TG ≥150 mg/dL) and low high-density lipoprotein (HDL ≤40 mg/dL) were significantly associated with an increased risk of PsA (HR=1.469 and HR=1.339, respectively).
• Poor glycemic control (HbA1c >7%) also showed a significant association with higher PsA risk (HR=1.144).
• No significant association was found between poor control of LDL (≥130 mg/dL) or uric acid (UA >6 mg/dL) and the risk of developing PsA.

Conclusions:

• Management of triglyceride and HDL levels is important for potentially reducing the risk of psoriatic arthritis (PsA) in patients with psoriasis (PsO).
• These findings highlight the role of metabolic health in the pathogenesis of PsA.
• Further research may explore targeted metabolic interventions to mitigate PsA risk in PsO patients.